27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Canaccord Genuity is maintaining its bullish stance on bluebird bio Inc (NASDAQ:BLUE) and projects upside for the biotech following a positive patient response to bb2121, the company’s multiple myeloma treatment.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
John Newman maintains a Buy rating on bluebird bio with a $250 price target.
The Thesis
The potential for the multiple myeloma treatment is just beginning to become visible, Newman said in a Monday note.
“As the drug moves earlier and is combined or sequenced with other therapies, we would expect a massive improvement in both [progression-free survival] and [overall survival],” the analyst said.
Bb2121 showed a median progression-free survival of 11.8 months, which fell in line with expectations, and the analyst said is impressive given the fact that the patients receiving the drug had already failed every therapy on the market.
Bluebird's next data catalyst could come at the Amercian Society of Hematology conference in December in San Diego and should "allay any concerns on an efficiency level," Newman said.
Related Links:
Leerink: Bluebird Bio's Catalysts Are Priced In
William Blair: Bluebird Bio Could See Another 'Blue Ribbon Year' In 2018
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.